fda warning letter hims & hers compounded semaglutide september 2025 falls 8% as issues over weight loss drug FDA Crackdown on Compounded GLP-1

Liposomal delivery protects the antioxidant, allowing it to be absorbed at the cellular level where it can actually work

People are filing Ozempic lawsuits that claim Novo Nordisk knew or should have known about the risk of severe side effects like vision loss, gastroparesis, gastroenteritis, intestinal blockage, blood clots and other severe health problems but failed to warn users

Incidence of chronic obstructive pulmonary disease in people with HIV, their parents and siblings in Denmark

The BMS 2025 Protocol: Optimising Your HRT and Weight Loss Journey The British Menopause Society (BMS) updated its guidance in April 2026 to address the increasing use of GLP-1 receptor agonists among menopausal women

That's just one exampleof many